Junior Research Groups

Dr. Kaspar Burger

Non-coding RNA in health and disease

The human non-coding genome contains a large number on long and small non-coding RNA transcripts, which regulate gene expression at various levels. The production and processing of such transcripts requires tight mechanisms of control to avoid the accumulation of aberrant transcripts to pathogenic levels. Members of the RNase III enzyme family, such as Dicer, maintain low levels of double-stranded RNA species, which otherwise engage a cellular defence mechanism termed innate immunity. Impaired dsRNA processing by Dicer mutation is also detrimental for the stability of the genome. Our research explores the links between the RNA metabolism, innate immunity and genome maintenance to understand how pathogenic RNA promotes tumorigenesis.

E-MailLab Homepage

Dr. Kai Kretzschmar

Modelling head and neck cancer using epithelial organoid cultures

Head and neck squamous cell carcinoma (HNSCC) is amongst the most common cancer types worldwide. To unravel the cellular and molecular basis of HNSCC, my laboratory applies organoid technology, which allows for the culture of ‘mini-tumours’ and ‘mini-tissues’ in a dish. We have optimised protocols for the generation of organoids from both normal human oral mucosa as well as head and neck cancer tissue. Cancer cells frequently remodel their microenvironment (‘niche’) to support their growth and protect them from the immune system (‘immune escape’). To explore immune escape mechanisms, we therefore use co-cultures of HNSCC organoids and immune cells.


Dr. Leo Rasche

Dissecting Multiple Myeloma and its microenvironment with state-of-the-art technology

Multiple Myeloma is the most common cancer of the bone marrow (BM). Despite significant improvement in overall survival, most patients develop refractory disease and myeloma remains largely incurable. Myeloma is the paradigm of a tumor in its microenvironment. Similar to healthy plasma cells, myeloma cell survival is dependent on specific cell-cell interactions with non-malignant cells in the BM. This interplay takes place in the plasma cell survival niche, a poorly characterized micro-anatomical structure along the BM capillaries. In this niche, oxygen supply and nutrients are restricted, which creates a unique metabolic environment. Our group explores this multicellular ecosystem using state of the art technology with the aim to develop novel treatments for myeloma.


Dr. Angela Riedel

Stromal reprogramming of tumour draining lymph nodes in metastatic dissemination and tumour immune evasion

Metastatic disease and tumour immune evasion are two major hurdles in cancer therapy. Tumour-draining lymph nodes (TDLNs) are immunological hubs and often the first site where metastatic tumour cells are detected. We are interested in the cells of the metastatic TDLN niche, the so called stroma, and how these influence metastatic spread and anti-tumour immune responses. A main goal is to characterize the cellular cross-talk between tumour cells, cells of the immune system and the LN stroma. To do so we use an interdisciplinary approach by combining complex in vitro models, mouse models and patient samples with single-cell profiling techniques, metabolomics and proteomics.